Abstract: The present invention provides for compositions, kits and methods for treatment of intraepithelial neoplasia, where the compositions include catecholic butanes, which include NDGA derivatives.

Abstract: The present invention provides kits, methods and compositions for the treatment of diseases such as cancers. The compositions herein contain a substantially pure preparation of at least one catecholic butane, including, for example, NDGA compounds in a pharmaceutically acceptable carrier or excipient. The catecholic butane such as NDGA or its derivatives are administered to one or more subjects in need of treatment by a route other than direct injection into the affected tissues or topical application on affected tissues.

Abstract: The present invention provides kits, methods and compositions for the treatment of tumor and other proliferative diseases such as tumors. The compositions herein contain a substantially pure preparation of at least one catecholic butane, including, for example, NDGA compounds in a pharmaceutically acceptable carrier or excipient. The catecholic butane such as NDGA or its derivatives are administered to one or more subjects in need of treatment by a route other than direct injection into the affected tissues or topical application on affected tissues.

Abstract: Methods are described for treating an influenza viral infection or associated diseases, disorders or mechanisms in a subject, comprising administering to the subject a therapeutically effective amount of a catecholic butane of the general formula (I) or a pharmaceutically acceptable salt thereof: wherein R1 and R2 each independently represents a hydrogen, a lower alkyl, a lower acyl, an alkylene, or —OR1 and —OR2 each independently represents an unsubstituted or substituted amino acid residue or pharmaceutically acceptable salt thereof; R3, R4, R5, R6, R10, R11, R12 and R13 each independently represents a hydrogen, or a lower alkyl; and R7, R8 and R9 each independently represents a hydrogen, —OH, a lower alkoxy, a lower acyloxy, an unsubstituted or substituted amino acid residue or pharmaceutically acceptable salt thereof, or any two adjacent groups together may be an alkyene dioxy; with the proviso in certain circumstances that where one of R7, R8 and R9 represents a hydrogen, then —OR1, —OR2 and the oth

Abstract: The present invention provides for compositions, kits and methods for treatment of intraepithelial neoplasia, where the compositions include catecholic butanes, which include NDGA derivatives.

Abstract: Disclosed are systems and methods for processing the releasing and/or dispensing of releasable items, particularly pills, capsules, tablets, medications, and drugs. In one embodiment, a system for processing the releasing and/or dispensing releasable items includes a releasing unit configured to verify whether a cartridge is authorized for usage with a releasing unit. The releasing unit is further configured to send data corresponding to the releasable items and the activities of the items via a network and/or telephone line. The system further includes a central-computing device configured to receive the data via the network and/or telephone line and provide a database of the data to a provider, e.g., pharmacist.

Abstract: Disclosed are systems and methods for processing the releasing and/or dispensing of releasable items, particularly pills, capsules, tablets, medications, and drugs. In one embodiment, a system for processing the releasing and/or dispensing releasable items includes a releasing unit configured to verify whether a cartridge is authorized for usage with a releasing unit. The releasing unit is further configured to send data corresponding to the releasable items and the activities of the items via a network and/or telephone line. The system further includes a central-computing device configured to receive the data via the network and/or telephone line and provide a database of the data to a provider, i.e., pharmacist.

Abstract: The present invention provides kits, methods and compositions for the treatment of tumor and other proliferative diseases such as tumors. The compositions herein contain a substantially pure preparation of at least one catecholic butane, including, for example, NDGA compounds in a pharmaceutically acceptable carrier or excipient. The catecholic butane such as NDGA or its derivatives are administered to one or more subjects in need of treatment by a route other than direct injection into the affected tissues or topical application on affected tissues.

Abstract: The present invention provides kits, methods and compositions for the treatment of diseases, such as, for example, non-cancer proliferative diseases, neurodegenerative diseases, diabetes and hypertension. The compositions herein contain a substantially pure preparation of at least one catecholic butane, including, for example, NDGA Compounds in a pharmaceutically acceptable carrier or excipient by various routes of administration.

Abstract: The present invention relates to a chromatography column that removes the longitudinal load from the column tube altogether and transfers it to a yoke and stanchion arrangement situated around but external to the column tube. By using the yoke/stanchion system, the central adjuster can be used to move the top end into and out of the housing. Thus, when internal pressure is applied to the column, the tube experiences no longitudinal load. Additionally, the yoke and stanchion design allows for complete removal of the end from the tube without cumbersome disassembly. Moreover, the yoke provides a place to retain the end while the tube is being filled, emptied, cleaned or repaired.

Abstract: The present invention relates to a chromatography column that removes the longitudinal load from the column tube altogether and transfers it to a yoke and stanchion arrangement situated around but external to the column tube. By using the yoke/stanchion system, the central adjuster can be used to move the top end into and out of the housing. Thus, when internal pressure is applied to the column, the tube experiences no longitudinal load. Additionally, the yoke and stanchion design allows for complete removal of the end from the tube without cumbersome disassembly. Moreover, the yoke provides a place to retain the end while the tube is being filled, emptied, cleaned or repaired.

Abstract: A seal on a movable top or bottom plate for use in a chromatography column. The plate is formed of a flow distributor connected to one or more movement rods that control the movement of the top plate within a chromatography column. The plate is formed of two pieces, a flow distributor and a seal plate. The seal plate is mounted on top of the flow distributor and has a seal that is essentially co-terminal with the outer edge of the flow distributor. The seal plate is attached to the flow distributor by one or more pins or threaded bolts and forms a space between them. The one or more pins contain one or more compression means for biasing the seal plate against the flow distributor. An opening is formed in the seal plate for the selective introduction of a pressurized energy source such as compressed air, gas or hydraulic fluid into the space to overcome the compression means. One or more seals are arranged between the seal plate and distributor to maintain the pressurized energy source between the two of them.

Abstract: Disclosed are systems and methods for processing the releasing and/or dispensing of releasable items, particularly pills, capsules, tablets, medications, and drugs. In one embodiment, a system for processing the releasing and/or dispensing releasable items includes a releasing unit configured to verify whether a cartridge is authorized for usage with a releasing unit. The releasing unit is further configured to send data corresponding to the releasable items and the activities of the items via a network and/or telephone line. The system further includes a central-computing device configured to receive the data via the network and/or telephone line and provide a database of the data to a provider, i.e., pharmacist.

Abstract: A chromatography column having at least one central slurry valve positioned at either the top cell assembly and/or the bottom cell assembly. The central slurry valves have a pneumatically actuated valve sleeve which can be shifted to create three different flow configurations. One flow configuration allows for the simultaneous cleaning in place of the flow path used to charge the column with chromatography media and the separate processing of fluid through the chromatography media. The other flow configurations permit the reslurrying and removal of chromatography media from the column, and the subsequent repacking of the column with fresh chromatography media without disassembling the column.

Abstract: To determine the speed of propagation of a signal in a medium, wave amplitude is measured over time at one or more detectors disposed within the medium so as to detect and identify signals transmitted at one or more sources disposed within said region. Frequency domain matched field processing power is calculated by matching measured with perturbation normal mode model fields, and beta coefficients which determine sound speed profiles are calculated by beta backpropagation so as to maximize the matched field processing power.